Intervention not reported
Infection‐related mortality Rates of patients · breast cancer patients undergoing chemotherapy
The intervention showed no clear difference in infection‐related mortality Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
Severe neutropenia (WHO grade IV) Rates of patients · breast cancer patients undergoing chemotherapy
The intervention showed no clear difference in severe neutropenia (WHO grade IV) Rates of patients (moderate certainty).
1 finding from 1 review
Intervention not reported
Infections Rates of patients · breast cancer patients undergoing chemotherapy
The intervention showed no clear difference in infections Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
Hospitalization Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower hospitalization Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
Antibiotics (i.v.) Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower antibiotics (i.v.) Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
Bone pain Rates of patients · breast cancer patients undergoing chemotherapy
The intervention probably leads to higher bone pain Rates of patients (moderate certainty).
1 finding from 1 review
Quality of life · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall severe adverse events (grade > 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes overall severe adverse events (grade > 3) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes anaemia (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes hand‐foot syndrome (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Neurological (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes neurological (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes progression‐free survival (PFS) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Time to progression · participants with advanced or metastatic muscle invasive bladder cancer
It is very uncertain whether immune checkpoint inhibitors changes time to disease progression Range of compared with any second‐line chemotherapy (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review